Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2)-Reference-Cited by-同舟云学术

Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2)

Published:1997 Issue:2 Volume:5 Page:54-61
ISSN:1065-7541
Container-title:Radiation Oncology Investigations
language:en
Short-container-title:Radiat. Oncol. Investig.

Author:

Jürgenliemk-Schulz I.-M.,Renes I.B.,Rutgers D.H.,Everse L.A.,Bernsen M.R.,Den Otter W.,Battermann J.J.

Publisher

Wiley

Subject

Radiology Nuclear Medicine and imaging,Oncology,Radiological and Ultrasound Technology,Radiation

Reference37 articles.

1. , : Late effects of cancer treatment: Radiation and drug toxicity. In (eds): Principles and Practice of Radiation Oncology. Philadelphia: J.B. Lippincott, pp 124–161, 1992.

2. : Principles of fractionation in radiotherapy. In (ed): Radiobiology in Radiotherapy. London: Springer-Verlag, pp 53–58, 1988.

3. Fractionation in radiotherapy

4. Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

5. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma;Clinical Cancer Research;2021-09-22

2. Immunotherapy as sensitizer for local radiotherapy;OncoImmunology;2020-01-01

3. Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?;Frontiers in Immunology;2018-12-11

4. Combining RAIT and Immune-Based Therapies to Overcome Resistance in Cancer?;Resistance to Targeted Anti-Cancer Therapeutics;2018

5. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences;Immunological Reviews;2017-10-13